GNRHR and polycystic ovary syndrome: However, it remains to be assessed in future studies whether long-term preclinical treatments (i.e.: 3–6 months) with low doses of GnRH-R antagonists may have a potential benefit in correcting neuroendocrine and reproductive alterations of PCOS-like mice.